Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating CS-101 in Beta-thalassemia has completed. The study assessed the safety and preliminary efficacy of CS-101 in treated subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• CS-101

Snippet

Sponsor: CorrectSequence Therapeutics Co., Ltd | Conditions: Beta-Thalassemia | EARLY_Phase 1 | Status: COMPLETED